Clinical Trials Browser

INDUSTRY × Uveal Melanoma × Melphalan × Clear all

NCT02678572 2023-12-21

FOCUS

Phase 3 Completed

102 enrolled 1 FDA

Uveal Melanoma

NCT05022901 2023-12-21

An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma

Phase 3 Active not recruiting

Uveal Melanoma

NCT00324727 2021-06-21

Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma

Phase 3 Completed

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT00096083 2013-10-23

Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer

Phase 2 Completed

DermatologicEndocrineGastrointestinal

Adenocarcinoma Of Esophagus, Uveal Melanoma, Appendiceal Neoplasms, Bile Duct Neoplasms, Colonic Neoplasms, Vipoma, Esophageal Neoplasms, Gallbladder Neoplasms, Glucagonoma, Carcinoma, Hepatocellular, Insulinoma, Melanoma, Neoplasms, Pancreatic Neoplasms, Pheochromocytoma, Rectal Neoplasms, Somatostatinoma, Stomach Neoplasms, Carcinoma, Islet Cell, Carcinoma, Medullary

NCT01728051 2013-10-23

Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver

No longer available

DermatologicGastrointestinal

Uveal Melanoma, Liver Neoplasms, Melanoma